TC BioPharm Files 6-K Report

Ticker: TCBWF · Form: 6-K · Filed: Oct 7, 2025 · CIK: 1872812

Tc Biopharm (Holdings) PLC 6-K Filing Summary
FieldDetail
CompanyTc Biopharm (Holdings) PLC (TCBWF)
Form Type6-K
Filed DateOct 7, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: 6-K, regulatory-filing, foreign-private-issuer

TL;DR

TC BioPharm filed a 6-K on 10/7/25, confirming 20-F filing status.

AI Summary

TC BioPharm (Holdings) plc filed a Form 6-K on October 7, 2025, reporting as a foreign private issuer. The company, incorporated in Scotland, operates in the biological products sector and is located at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR. This filing is for the month of October 2025 and indicates the company files annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding TC BioPharm's status as a foreign private issuer. It confirms their reporting structure and location.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that does not contain new financial or operational information, making the immediate risk low.

Key Numbers

Key Players & Entities

FAQ

What type of filing is this Form 6-K?

This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

What is the filing date for this report?

The filing date for this report is 20251007 (October 7, 2025).

Does TC BioPharm file annual reports under Form 20-F or 40-F?

TC BioPharm indicates it files annual reports under cover of Form 20-F.

What is the principal executive office address for TC BioPharm?

The principal executive office address is Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, Scotland, United Kingdom.

What is the SIC code for TC BioPharm?

The Standard Industrial Classification (SIC) code for TC BioPharm is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 19.2 · Accepted 2025-10-07 07:00:19

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TC BIOPHARM (HOLDINGS) PLC Date: October 7, 2025 By: /s/ Martin Thorp Martin Thorp Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing